These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 14654555)
1. Properties of bisphosphonates in the 13762 rat mammary carcinoma model of tumor-induced bone resorption. Alvarez E; Westmore M; Galvin RJ; Clapp CL; Considine EL; Smith SJ; Keyes K; Iversen PW; Delafuente DM; Sulaimon S; Zambrano C; Ma L; Sato M; Martin TJ; Teicher BA; Galbreath EJ Clin Cancer Res; 2003 Nov; 9(15):5705-13. PubMed ID: 14654555 [TBL] [Abstract][Full Text] [Related]
2. Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells. Tenta R; Sourla A; Lembessis P; Koutsilieris M Anticancer Res; 2006; 26(1A):283-91. PubMed ID: 16475708 [TBL] [Abstract][Full Text] [Related]
3. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors. Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357 [TBL] [Abstract][Full Text] [Related]
4. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model. Yang M; Burton DW; Geller J; Hillegonds DJ; Hastings RH; Deftos LJ; Hoffman RM Clin Cancer Res; 2006 Apr; 12(8):2602-6. PubMed ID: 16638872 [TBL] [Abstract][Full Text] [Related]
5. Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo. Fournier PG; Daubiné F; Lundy MW; Rogers MJ; Ebetino FH; Clézardin P Cancer Res; 2008 Nov; 68(21):8945-53. PubMed ID: 18974139 [TBL] [Abstract][Full Text] [Related]
6. Breast cancer bone metastasis and current small therapeutics. Cicek M; Oursler MJ Cancer Metastasis Rev; 2006 Dec; 25(4):635-44. PubMed ID: 17160709 [TBL] [Abstract][Full Text] [Related]
7. Bone microenvironment-related growth factors, zoledronic acid and dexamethasone differentially modulate PTHrP expression in PC-3 prostate cancer cells. Tenta R; Sourla A; Lembessis P; Luu-The V; Koutsilieris M Horm Metab Res; 2005 Oct; 37(10):593-601. PubMed ID: 16278781 [TBL] [Abstract][Full Text] [Related]
9. Effects of transforming growth factor-beta1 on parathyroid hormone-related protein mRNA expression and protein secretion in canine prostate epithelial, stromal, and carcinoma cells. Sellers RS; LeRoy BE; Blomme EA; Tannehill-Gregg S; Corn S; Rosol TJ Prostate; 2004 Mar; 58(4):366-73. PubMed ID: 14968437 [TBL] [Abstract][Full Text] [Related]
10. Mechanisms of osteolytic bone metastases in breast carcinoma. Käkönen SM; Mundy GR Cancer; 2003 Feb; 97(3 Suppl):834-9. PubMed ID: 12548583 [TBL] [Abstract][Full Text] [Related]
11. Osteoblast proliferation and maturation by bisphosphonates. Im GI; Qureshi SA; Kenney J; Rubash HE; Shanbhag AS Biomaterials; 2004 Aug; 25(18):4105-15. PubMed ID: 15046901 [TBL] [Abstract][Full Text] [Related]
12. 2-Methoxyestradiol suppresses osteolytic breast cancer tumor progression in vivo. Cicek M; Iwaniec UT; Goblirsch MJ; Vrabel A; Ruan M; Clohisy DR; Turner RR; Oursler MJ Cancer Res; 2007 Nov; 67(21):10106-11. PubMed ID: 17974950 [TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Bierie B; Stover DG; Abel TW; Chytil A; Gorska AE; Aakre M; Forrester E; Yang L; Wagner KU; Moses HL Cancer Res; 2008 Mar; 68(6):1809-19. PubMed ID: 18339861 [TBL] [Abstract][Full Text] [Related]
14. Antisense inhibition of parathyroid hormone-related peptide gene expression reduces malignant pituitary tumor progression and metastases in the rat. Akino K; Ohtsuru A; Yano H; Ozeki S; Namba H; Nakashima M; Ito M; Matsumoto T; Yamashita S Cancer Res; 1996 Jan; 56(1):77-86. PubMed ID: 8548779 [TBL] [Abstract][Full Text] [Related]
15. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. Guise TA; Yin JJ; Taylor SD; Kumagai Y; Dallas M; Boyce BF; Yoneda T; Mundy GR J Clin Invest; 1996 Oct; 98(7):1544-9. PubMed ID: 8833902 [TBL] [Abstract][Full Text] [Related]
16. Production of granulocyte-stimulating and bone cell-modulating activities from a neutrophilia hypercalcemia-inducing murine mammary cancer cell line. Lee MY; Liu CC; Lottsfeldt JL; Judkins SA; Howard GA Cancer Res; 1987 Aug; 47(15):4059-65. PubMed ID: 3496955 [TBL] [Abstract][Full Text] [Related]
17. In vivo luminescent imaging of cyclosporin A-mediated cancer progression in rats. Ohsawa I; Murakami T; Uemoto S; Kobayashi E Transplantation; 2006 Jun; 81(11):1558-67. PubMed ID: 16770245 [TBL] [Abstract][Full Text] [Related]
18. Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice. Cui N; Nomura T; Noma H; Yokoo K; Takagi R; Hashimoto S; Okamoto M; Sato M; Yu G; Guo C; Shibahala T Clin Cancer Res; 2005 Apr; 11(7):2713-9. PubMed ID: 15814653 [TBL] [Abstract][Full Text] [Related]
19. New results from the use of bisphosphonates in cancer patients. Coleman R; Gnant M Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507 [TBL] [Abstract][Full Text] [Related]
20. Parathyroid hormone-related protein protects against mammary tumor emergence and is associated with monocyte infiltration in ductal carcinoma in situ. Fleming NI; Trivett MK; George J; Slavin JL; Murray WK; Moseley JM; Anderson RL; Thomas DM Cancer Res; 2009 Sep; 69(18):7473-9. PubMed ID: 19723659 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]